TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ... with the remaining 3 patients currently completing ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart ... with the remaining 3 patients currently completing Part ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

[9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled Surveillance of North American Pulmonary Hypertension (SNAP). The goal of the ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...